短缺对药品价格的影响：对短缺预防的启示。
The Impact of Shortages on Medication Prices: Implications for Shortage Prevention.
机构信息
Infectious Diseases Division, Rhode Island Hospital, Warren Alpert Medical School of Brown University, 593 Eddy Street, POB, 3rd Floor, Suite 328/330, Providence, RI, 02903, USA.
Biostatistics Core, Lifespan Hospital System and Departments of Orthopaedics and Surgery, Warren Alpert Medical School of Brown University, Providence, RI, USA.
出版信息
Drugs. 2016 Oct;76(16):1551-1558. doi: 10.1007/s40265-016-0651-7.
BACKGROUND
Medication shortages are frequent and have clinical and financial ramifications; however, their effect on drug prices remains unknown.
OBJECTIVE
To examine price progression of medications affected by a shortage.
METHODS
We collected prices of medications covered under Medicare Part B, reflective of general market prices, and data on clinically relevant shortages for the period 2005-16. We used linear mixed-effects models to examine the price growth of affected medications.
RESULTS
Shortage medications demonstrated a quarterly price growth of -0.5 % (95 % confidence interval [CI] -1.6, 0.6) in the period preceding a shortage, 4.3 % (95 % CI 3.6, 4.5) during a shortage, and 4.1 % (95 % CI 2.6, 5.5) in the post-shortage period. Medications not affected by a shortage had a quarterly price growth of 0.2 % (95 % CI -0.3, 0.6).
CONCLUSIONS
Medication shortages are associated with price increases, and these increases are likely reactive to the low profitability of the affected medications and thus, proactive collaboration between the US Food and Drug Administration and industry can serve to identify low-profit drugs and evaluate measures to ensure continued production.
背景
药物短缺频繁发生，对临床和财务都有影响；然而，其对药品价格的影响尚不清楚。
目的
研究受短缺影响的药物价格变化情况。
方法
我们收集了医疗保险计划 B 部分涵盖的药物价格数据，这些药物价格反映了一般市场价格，以及 2005 年至 2016 年期间与临床相关的短缺数据。我们使用线性混合效应模型来研究受短缺影响的药物价格增长情况。
结果
在短缺发生前，短缺药物的季度价格增长率为-0.5%（95%置信区间：-1.6%，0.6%），在短缺期间为 4.3%（95%置信区间：3.6%，4.5%），在短缺后期间为 4.1%（95%置信区间：2.6%，5.5%）。未受短缺影响的药物的季度价格增长率为 0.2%（95%置信区间：-0.3%，0.6%）。
结论
药物短缺与价格上涨有关，这些上涨可能是对受影响药物低利润的反应，因此，美国食品和药物管理局与行业之间的积极合作可以识别低利润药物，并评估确保持续生产的措施。
Zotero 插件